Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 7.42 Billion | USD 12.36 Billion | 6.55% | 2022 |
The global typhoid antibody testing market size was worth around USD 7.42 billion in 2022 and is predicted to grow to around USD 12.36 billion by 2030 with a compound annual growth rate (CAGR) of roughly 6.55% between 2023 and 2030.
Typhoid antibody testing is a medical test conducted to diagnose and confirm typhoid fever in a patient. These tests are used to detect the presence of IgG and IgM antibodies that are released by the body when a person is infected by the bacteria called Salmonella Typhi causing typhoid fever. The antibodies play the role of fighting the virus and if typhoid antibody testing detects the presence of IgM and IgG, medical professionals can confirm that a person has contracted typhoid and they can start appropriate medication.
Typhoid is a common medical condition occurring in several countries, especially in underdeveloped and developing nations. Typhoid fever does not occur in places that have effective waste management systems or where water is treated to kill all types of germs. It is caused by consuming contaminated food or water and in some cases, it can also be contagious for people living in proximity of other patients affected by typhoid. Once the treatment starts, a patient may start feeling better in a week’s time but the medication continues for a longer period to ensure complete eradication of the Salmonella Typhi bacteria from the system.
Increasing prevalence of the disease in developing nations to drive market growth
The global typhoid antibody testing market is projected to grow owing to the increasing prevalence of typhoid in developing and underdeveloped nations. Currently, South Asia and Africa are the two regions with the most number of typhoid cases. The rising regional population rate along with the non-availability of safe drinking water or food for a larger segment of the people are the driving factors for the increasing rate of confirmed typhoid cases. A report filed by the United Nations (UN) and the United Nations Educational, Scientific, and Cultural Organization (UNESCO) submitted at the 2023 Water Conference suggests that nearly 26% across the globe do not have access to safe and germ-free water. Additionally, around 46% live in areas with improperly managed sanitation areas. Several factors contribute to the rising rate of water pollution which is a leading reason for several medical diseases including typhoid. These factors include the release of industrial discharge in water bodies, oil spills, mining & construction activities, urban run-off, and agricultural run-off. Increasing consumerism is a significant aspect of water pollution.
Rising collaborative effort aimed at the development of new testing tools to push market revenue
The players operating in the typhoid antibody testing industry are working on several projects for improved management of the disease. In August 2023, Vaxxas and SK Bioscience announced the start of a joint collaboration through which the companies will develop a new vaccine-delivery device combination product leveraging the technical and biological expertise of both companies. SK Bioscience will provide its proprietary typhoid vaccine while Vaxxas will be responsible for enlisting the help of its high-density microarray patch (HD-MAP) platform technology.
Lack of accurate diagnosis during the early stages of the disease to restrict market growth
Typhoid-associated symptoms include stomach pain, headache, high fever, and diarrhea or constipation. These symptoms are associated with several other types of medical conditions as well. Studies indicate that over 90% of patients with typhoid go undiagnosed or undetected during the early stages of the disease. In addition to this, in certain instances, there are no obvious signs shown by the patient or the incubation period is longer than expected. All of these factors create growth limitations in the global typhoid antibody testing market and more advanced or rapid diagnostics are required so that accurate medication can be started as soon as the patient is infected.
Growing work toward the development of novel typhoid antibody tests to create further opportunities
The typhoid antibody testing industry may come across several growth opportunities led by rising innovation and the development of novel typhoid antibody tests. For instance, in April 2023, Vanguard Diagnostics, a Delhi-based player, launched the VANSCAN Typhoid RT PCR Test. The company has developed the new test in association with Graphic Era University and is a patented technology along with being labeled as one-of-a-kind in the Indian market. VANSCAN Typhoid RT PCR Test is the answer to the growing obsolescence of the Widal test.
In June 2022, a new typhoid-detecting technique was developed by an international group of researchers which is expected to improve vaccination planning in countries impacted by the condition. This new approach deals with detecting typhoid antibodies in dried blood spots thus leading to a faster and more accurate test result as compared to the ones obtained from blood cultures. Around 1420 blood samples of confirmed typhoid cases were collected from South Asian countries for the development of the technology that relies on the response generated by antibodies.
Lack of awareness about typhoid antibody testing methods in remote areas may create challenging situations
The global typhoid antibody testing market growth is likely to be challenged by the lack of awareness about typhoid antibody testing methods, especially the most advanced and recent testing tools. This trend is generally observed in remote areas with no proper access to healthcare centers or education programs imparting knowledge on the causes and treatments available for the disease. Additionally, the cost of testing can lead to people from the lower-income groups refraining from undergoing testing which is a crucial aspect of maintaining or improving regional population health.
The global typhoid antibody testing market is segmented based on end-user, product type, and region.
Based on end-user, the global market segments are hospitals, serological testing centers, clinics, diagnostic centers, and others. In 2022, the highest growth was observed in the diagnostic centers and hospitals segments. These units typically have larger patient footfalls and conduct numerous tests every day. In addition to this, hospitals, in particular, act as complete units of medical care with easy availability of testing facilities and doctors or medical staff. The rising number of diagnostic centers across the globe is likely to improve segmental revenue during the forecast period. In July 2023, India’s leading diagnostic unit Vijaya Diagnostic Center opened its 104th store in Kolkata.
Based on product type, the typhoid antibody testing industry is divided into rapid serological tests, typhidot test, and Widal test. The rapid serological tests segment is further divided into hemagglutination & co-agglutination and counter immunoelectrophoresis. The global market was dominated by the Widal test in 2022 however, the segment is likely to receive a lesser response during the forecast period with more demand for the growing rapid serological tests as they are novel systems with better accuracy and response time. They are also more user-friendly and have gained an excellent acceptance rate in the medical community. If the condition is detected in early stages and medication starts on time, the patient may be relieved of typhoid in 7 to 14 days.
Report Attributes | Report Details |
---|---|
Report Name | Typhoid Antibody Testing Market |
Market Size in 2022 | USD 7.42 Billion |
Market Forecast in 2030 | USD 12.36 Billion |
Growth Rate | CAGR of 6.55% |
Number of Pages | 222 |
Key Companies Covered | Siemens Healthineers, BD (Becton, Dickinson and Company), Thermo Fisher Scientific, Bio-Rad Laboratories, Meridian Bioscience, Abbott Laboratories, Creative Diagnostics, BioMérieux, InBios International, DiaSorin., and others. |
Segments Covered | By End-User, By Product Type, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Asia-Pacific to witness the highest growth during the forecast timeline
The global typhoid antibody testing market is expected to witness the highest growth in Asia-Pacific during the forecast period mainly due to the higher prevalence rate of the condition in South Asian countries. The presence of poor-quality water bodies and lack of proper sanitation are leading reasons for growing cases of typhoid in this region. Other factors include overcrowding due to rampant but unplanned urbanization and city development projects.
An official report by the National Institute of Health (NIH) estimates the prevalence rate of the condition in India is around 360 cases per 100,000 people. However, in recent times, the regional governments have undertaken massive projects such as the incorporation of typhoid vaccination in routine immunization programs by Nepal and Pakistan. Additionally, the increasing number of diagnostic centers and investments in improving regional healthcare infrastructure could further promote substantial growth. Africa is expected to register significant growth due to improving access to medical care. Moreover, the region has witnessed increased vaccination and educational drives from international agencies to curb typhoid cases in the region.
The global typhoid antibody testing market is led by players like:
By End-User
By Product Type
FrequentlyAsked Questions
Typhoid antibody testing is a medical test conducted to diagnose and confirm typhoid fever in a patient.
The global typhoid antibody testing market is projected to grow owing to the increasing prevalence of typhoid in developing and underdeveloped nations.
According to study, the global typhoid antibody testing market size was worth around USD 7.42 billion in 2022 and is predicted to grow to around USD 12.36 billion by 2030
The CAGR value of typhoid antibody testing market is expected to be around 6.55% during 2023-2030.
The global typhoid antibody testing market is expected to witness the highest growth in Asia-Pacific during the forecast period mainly due to the higher prevalence rate of the condition in South Asian countries.
The global typhoid antibody testing market is led by players like Siemens Healthineers, BD (Becton, Dickinson, and Company), Thermo Fisher Scientific, Bio-Rad Laboratories, Meridian Bioscience, Abbott Laboratories, Creative Diagnostics, BioMérieux, InBios International, and DiaSorin.
The report explores crucial aspects of the typhoid antibody testing market including a detailed discussion of existing growth factors and restraints while also browsing future growth opportunities and challenges that impact the market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed